Filing Details

Accession Number:
0001209191-23-002895
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-01-10 20:30:16
Reporting Period:
2023-01-06
Accepted Time:
2023-01-10 20:30:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070494 Acadia Pharmaceuticals Inc ACAD Pharmaceutical Preparations (2834) 061376651
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1891900 Brendan Teehan C/O Acadia Pharmaceuticals Inc.
12830 El Camino Real, Suite 400
San Diego CA 92130
Evp, Coo, Head Of Commercial No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-01-06 1,286 $0.00 5,081 No 4 M Direct
Common Stock Disposition 2023-01-09 532 $17.13 4,549 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2022-01-06 1,286 $0.00 1,286 $0.00
Common Stock Restricted Stock Units Disposition 2023-01-06 1,286 $0.00 1,286 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
2,573 No 4 M Direct
1,287 No 4 M Direct
Footnotes
  1. Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.
  2. Includes 358 shares of the Issuer's common stock acquired by the reporting person on May 16, 2022 pursuant to an employee stock purchase program.
  3. The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.13 to $17.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
  5. This restricted stock units is being re-reported solely to correct vesting terms on the Form 4 filed on January 10, 2022, which erroneously indicated that the restricted stock units vest in four equal annual installments beginning January 6, 2021. The correct vesting is one-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported.
  6. One-third of the shares subject to the restricted stock units vest on each of January 6, 2022, January 6, 2023 and January 6, 2024.